- Home
- NXGL vs BLRX Comparison
NXGL vs BLRX Comparison
Compare NXGL & BLRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NXGL
- BLRX
- Stock Information
- Founded
- NXGL 1997
- BLRX 2003
- Country
- NXGL United States
- BLRX Israel
- Employees
- NXGL N/A
- BLRX N/A
- Industry
- NXGL Medical/Dental Instruments
- BLRX Biotechnology: Pharmaceutical Preparations
- Sector
- NXGL Health Care
- BLRX Health Care
- Exchange
- NXGL Nasdaq
- BLRX Nasdaq
- Market Cap
- NXGL 18.7M
- BLRX 17.2M
- IPO Year
- NXGL 2021
- BLRX 2011
- Fundamental
- Price
- NXGL $2.55
- BLRX $3.88
- Analyst Decision
- NXGL
- BLRX Strong Buy
- Analyst Count
- NXGL 0
- BLRX 2
- Target Price
- NXGL N/A
- BLRX $19.00
- AVG Volume (30 Days)
- NXGL 44.4K
- BLRX 32.7K
- Earning Date
- NXGL 11-12-2025
- BLRX 08-14-2025
- Dividend Yield
- NXGL N/A
- BLRX N/A
- EPS Growth
- NXGL N/A
- BLRX N/A
- EPS
- NXGL N/A
- BLRX N/A
- Revenue
- NXGL $11,672,000.00
- BLRX $17,251,000.00
- Revenue This Year
- NXGL $46.60
- BLRX N/A
- Revenue Next Year
- NXGL $47.96
- BLRX N/A
- P/E Ratio
- NXGL N/A
- BLRX N/A
- Revenue Growth
- NXGL 133.02
- BLRX 1.19
- 52 Week Low
- NXGL $2.10
- BLRX $2.30
- 52 Week High
- NXGL $5.10
- BLRX $26.80
- Technical
- Relative Strength Index (RSI)
- NXGL 56.42
- BLRX 51.00
- Support Level
- NXGL $2.39
- BLRX $3.68
- Resistance Level
- NXGL $2.65
- BLRX $4.11
- Average True Range (ATR)
- NXGL 0.19
- BLRX 0.25
- MACD
- NXGL 0.03
- BLRX 0.03
- Stochastic Oscillator
- NXGL 72.73
- BLRX 48.94
About NXGL NexGel Inc
NexGel Inc manufactures high water content, electron beam cross-linked, aqueous polymer hydrogels, or gels, used for wound care, medical diagnostics, transdermal drug delivery, and cosmetics. The company specializes in custom gels by capitalizing on proprietary manufacturing technologies. The gels and consumer products are manufactured using proprietary and non-proprietary mixing, coating and cross-linking technologies.
About BLRX BioLineRx Ltd.
BioLine Rx Ltd is a commercial-stage biopharmaceutical company focused on oncology. The company's current development and commercialization pipeline consists of two clinical-stage therapeutic candidates motixafortide (BL-8040), a novel peptide for the treatment of stem-cell mobilization and solid tumors, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, the company has a legacy therapeutic product called BL-5010 for the treatment of skin lesions. The company has generated revenues from milestone payments under previously existing out-licensing agreements.